stockrowAscendis Pharma A/S
ASND Healthcare Biotechnology
Ascendis Pharma A/S’s revenue for fiscal 2025 (year ended December 2025) was $814.8 million, up 107.1% from fiscal 2024.
- Revenue
- +119.9%
- EPS
- +612.3%
- Free cash flow
- +2,335.9%
- Total debt
- −41.8%
Quarter to June 2026, against a year earlier
Follow ASND
Alert me
Ascendis Pharma A/S (ASND) Book value per share
Ascendis Pharma A/S's book value per share at the end of fiscal 2025 was −3.0×, compared with −2.0× in fiscal 2024. At the end of the quarter to 30 June 2026 it was 26.0×. Over the past ten years it has ranged from −3.0× (fiscal 2025) to 19.1× (fiscal 2021) — the current reading is the lowest in ten years. Ascendis Pharma A/S ranks 26th of 611 Biotechnology companies by book value per share.
Book value per share, annual
Embed this chart
Annual newest first
| Period | Book value per share | Change |
|---|---|---|
| FY2025 | −3.0× | — |
| FY2024 | −2.0× | — |
| FY2023 | −2.8× | — |
| FY2022 | 4.9× | (74.08%) |
| FY2021 | 19.1× | 0.84% |
| FY2020 | 18.9× | 31.63% |
| FY2019 | 14.4× | 78.63% |
| FY2018 | 8.1× | 27.93% |
| FY2017 | 6.3× | (14.47%) |
| FY2016 | 7.4× | 30.87% |
Quarterly newest first
| Period | Book value per share | Change |
|---|---|---|
| Jun 2026 | 26.0× | 180.34% |
| Mar 2026 | 9.3× | — |
| Dec 2025 | −3.0× | — |
| Sep 2025 | −3.3× | — |
| 42 more quarters | Free account |
Against its own ten years
Book value per share against peers
| Company | Book value per share |
|---|---|
| BNTX BioNTech SE Sponsored ADR compare | 81.8× |
| JAZZ Jazz Pharmaceuticals PLC compare | 64.8× |
| ALNY Alnylam Pharmaceuticals, Inc. compare | 26.9× |
| ASND Ascendis Pharma A/S | 26.0× |
| EXEL Exelixis, Inc. compare | 7.4× |
| INSM Insmed, Inc. compare | 3.3× |
| SMMT Summit Therapeutics PLC compare | 0.8× |
| HALO Halozyme Therapeutics, Inc. compare | −0.5× |
| BBIO BridgeBio Pharma, Inc. compare | −8.4× |
What Book value per share is
BV per Share tells an investor how much of a company’s accounting net worth stands behind each share.
(Shareholders Equity (Total) ÷ Shares (Basic, Weighted))
More on ASND
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement